Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saroglitazar - Zydus Cadila

Drug Profile

Saroglitazar - Zydus Cadila

Alternative Names: Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1

Latest Information Update: 07 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila; Zydus Discovery DMCC
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Phase III Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 09 Nov 2018 Pharmacodynamics data from preclinical trial in Non-alcoholic steatohepatitis presented at 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
  • 23 Aug 2018 Phase-II clinical trials in Non-alcoholic fatty liver disease (In adults, In the elderly) in USA (PO) (NCT03639623)
  • 21 Aug 2018 Zydus Discovery DMCC plans a phase II trial for Non-alcoholic fatty liver disease in liver transplant patients (In adults, In the elderly) in USA (PO) (NCT03639623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top